SWX:COPN

Stock Analysis Report

Executive Summary

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide.

Snowflake

Fundamentals

Exceptional growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Cosmo Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COPN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.0%

COPN

1.0%

CH Pharmaceuticals

0.5%

CH Market


1 Year Return

-42.5%

COPN

11.9%

CH Pharmaceuticals

14.8%

CH Market

Return vs Industry: COPN underperformed the Swiss Pharmaceuticals industry which returned 11.9% over the past year.

Return vs Market: COPN underperformed the Swiss Market which returned 14.8% over the past year.


Shareholder returns

COPNIndustryMarket
7 Day-2.0%1.0%0.5%
30 Day-8.8%4.5%3.4%
90 Day-18.5%6.5%5.3%
1 Year-42.5%-42.5%22.2%11.9%20.4%14.8%
3 Year-60.0%-60.4%54.1%32.4%43.1%24.7%
5 Year-52.0%-53.0%27.2%2.4%35.1%13.6%

Price Volatility Vs. Market

How volatile is Cosmo Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cosmo Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: COPN (CHF70.1) is trading above our estimate of fair value (CHF12.47)

Significantly Below Fair Value: COPN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COPN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: COPN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate COPN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: COPN is good value based on its PB Ratio (2.3x) compared to the CH Pharmaceuticals industry average (3.7x).


Next Steps

Future Growth

How is Cosmo Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

80.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: COPN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: COPN's is expected to become profitable in the next 3 years.

Revenue vs Market: COPN's revenue (47.5% per year) is forecast to grow faster than the Swiss market (3.5% per year).

High Growth Revenue: COPN's revenue (47.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COPN's Return on Equity is forecast to be high in 3 years time (28%)


Next Steps

Past Performance

How has Cosmo Pharmaceuticals performed over the past 5 years?

-61.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COPN has high quality earnings.

Growing Profit Margin: COPN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: COPN is unprofitable, and losses have increased over the past 5 years at a rate of -61.8% per year.

Accelerating Growth: Unable to compare COPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: COPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.9%).


Return on Equity

High ROE: COPN has a negative Return on Equity (-7.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cosmo Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: COPN's short term assets (€351.6M) exceeds its short term liabilities (€16.4M)

Long Term Liabilities: COPN's short term assets (€351.6M) exceeds its long term liabilities (174.0M)


Debt to Equity History and Analysis

Debt Level: COPN's debt to equity ratio (38.9%) is considered satisfactory.

Reducing Debt: COPN's debt to equity ratio has increased from 1.2% to 38.9% over the past 5 years.

Debt Coverage: COPN's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if COPN's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: COPN has a low level of unsold assets or inventory.

Debt Coverage by Assets: COPN's debt is covered by short term assets (assets are 2.2x debt).


Next Steps

Dividend

What is Cosmo Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.08%

Forecast Dividend Yield


Dividend Yield vs Market

company0%marketbottom25%1.8%markettop25%3.6%industryaverage3.0%forecastin3Years1.1%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate COPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate COPN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if COPN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COPN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: COPN is not paying a notable dividend for the Swiss market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COPN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

What is the CEO of Cosmo Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

6.9yrs

Average management tenure


CEO

Alessandro Della Chà (56yo)

5.7yrs

Tenure

€1,671,169

Compensation

Mr. Alessandro E. Della Chà, LL.M, has been the Chief Executive Officer of Cosmo Pharmaceuticals N.V. (formerly Cosmo Pharmaceuticals S.p.A) since March 27, 2014 and also has been its Executive Director si ...


CEO Compensation Analysis

Compensation vs Market: Alessandro's total compensation ($USD0.00) is below average for companies of similar size in the Swiss market ($USD969.53K).

Compensation vs Earnings: Alessandro's compensation has been consistent with company performance over the past year.


Management Age and Tenure

6.9yrs

Average Tenure

63yo

Average Age

Experienced Management: COPN's management team is seasoned and experienced (6.9 years average tenure).


Board Age and Tenure

10.7yrs

Average Tenure

62yo

Average Age

Experienced Board: COPN's board of directors are seasoned and experienced ( 10.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Massimo Pedrani (65yo)

    Head of Generics Business Development

    • Tenure: 0yrs
  • Blake Boland (59yo)

    Chief Sales Officer

    • Tenure: 3.1yrs
  • Chris Tanner (68yo)

    Head of Transactions Office & Executive Director

    • Tenure: 13.8yrs
    • Compensation: €780.65k
  • Roberto Villa (76yo)

    Chief Manufacturing Officer

    • Tenure: 0yrs
  • Luigi Moro (68yo)

    Chief Scientific Officer

    • Tenure: 20.2yrs
  • Mauro Ajani (64yo)

    Founder & Chairman

    • Tenure: 7.6yrs
    • Compensation: €1.45m
  • Giuseppe Cipriano (62yo)

    Chief Operating Officer

    • Tenure: 18.8yrs
  • Alessandro Della Chà (56yo)

    CEO & Executive Director

    • Tenure: 5.7yrs
    • Compensation: €1.67m
  • Davide Malavasi (46yo)

    Technical Director

    • Tenure: 8.2yrs
  • Niall Donnelly (45yo)

    CFO & Head of Investor Relations

    • Tenure: 3.4yrs

Board Members

  • Dieter Enkelmann (60yo)

    Non-Executive Director

    • Tenure: 13.8yrs
    • Compensation: €155.78k
  • William Sandborn

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Chris Tanner (68yo)

    Head of Transactions Office & Executive Director

    • Tenure: 13.8yrs
    • Compensation: €780.65k
  • Mauro Ajani (64yo)

    Founder & Chairman

    • Tenure: 7.6yrs
    • Compensation: €1.45m
  • Geert D’Haens

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Alessandro Della Chà (56yo)

    CEO & Executive Director

    • Tenure: 5.7yrs
    • Compensation: €1.67m
  • Silvio Danese

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Maria Roncarolo (65yo)

    Non-Executive Director

    • Tenure: 7.6yrs
    • Compensation: €155.78k
  • Ralf Kiesslich

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Kevin Donovan (60yo)

    Non-Executive Director

    • Tenure: 3.7yrs
    • Compensation: €140.40k

Company Information

Cosmo Pharmaceuticals N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cosmo Pharmaceuticals N.V.
  • Ticker: COPN
  • Exchange: SWX
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF1.031b
  • Shares outstanding: 14.62m
  • Website: https://www.cosmopharma.com

Number of Employees


Location

  • Cosmo Pharmaceuticals N.V.
  • Riverside II
  • Sir John Rogerson’s Quay
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
COPNSWX (SIX Swiss Exchange)YesNew Common SharesCHCHFMar 2007
C43DB (Deutsche Boerse AG)YesNew Common SharesDEEURMar 2007
CMOP.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDMar 2007
COPNZBATS-CHIXE (BATS 'Chi-X Europe')YesNew Common SharesGBCHFMar 2007
0RGILSE (London Stock Exchange)YesNew Common SharesGBCHFMar 2007

Biography

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERI ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 20:59
End of Day Share Price2019/11/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.